[ad_1]
Davis, California, January 21, 2022 /PRNewswire/ — ELEVAI LABS, INC. (“ELEVAI” or the “Company”), a biotechnology company harnessing the power of human stem cell exosomes to create the next generation of topical skin care products, is pleased to announce that it has signed A non-exclusive global distributor and trademark license agreement with DermapenWorld™ (“Dermapen”), a leading Australian-based beauty device company.
Ten years ago, Dermapen revolutionized the beauty industry by inventing the first automatic micro-needling pen, the original and trusted Dermapen™. DermapenWorld is a recognized leader in the microneedling industry, having delivered more than 3 million treatments worldwide and providing synergistic solutions,…
The full story is available on Benzinga.com
[ad_2]
Source link
